🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending
X-VAULT VERIFIED

Discovery Marketplace

Novel bioactive compound candidates identified by AI from 9,238 substances and 1.12M PubMed studies. Each discovery is cryptographically sealed as prior art.

14 sealed discoveries0 target clusters5 compound familiesX-Vault WORM chain
TYPE 1 — COMPOUND14 results

Sealed Discoveries

Single compounds with X-Vault proof-of-discovery. PDF report + Merkle hash.

SHARED LICENSE
Research Rights

Full discovery report + PDF + X-Vault seal. BiohacksAI retains 90% IP. You receive 10% royalty if patent arises.

EXCLUSIVE LICENSE
Commercial + Patent Rights

Full commercial and patent rights. BiohacksAI retains 10% royalty on any IP commercialisation. One buyer only.

ResearchLevel CExtremely rare

PALMOSTATIN B

L1CAM interactions

42.1
score
Studies
2
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
ResearchLevel BRare

PNU74654

Adaptive Immune System

44.6
score
Studies
6
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
Patent-GradeLevel CExtremely rare

M084

Stimuli-sensing channels

103.9
score
Studies
2
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
Patent-GradeLevel CExtremely rare

UROLITHIN D

Membrane Trafficking

118.1
score
Studies
2
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

MIDOSTAURIN

Hemostasis

153906.7
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

AST 487

Hemostasis

157764.5
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

NINTEDANIB

Neuronal System

163341.9
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

SU 014813

Signaling by ERBB2

173149.4
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

R 406

Hemostasis

201028.0
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

KW 2449

Hemostasis

209652.4
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

FEDRATINIB

Hemostasis

210111.2
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

TAE 684

Hemostasis

227484.2
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

MOLIBRESIB

Cell Cycle

259310.0
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
BiohackerLevel CExtremely rare

LESTAURTINIB

Hemostasis

291352.3
score
Studies
0
Sealed
Mar 8, 2026
Verified Record
LOCKED
🔒Full mechanism analysis
🔒Complete target mapping
🔒Pathway network
🔒Literature PMIDs
TYPE 3 — SCAFFOLD FAMILY5 results

Compound Families

Groups of understudied compounds with high target-profile similarity (Jaccard ≥ 0.5). Each family shares functional biology — potential novel series.

Research SignalLevel C
11
score

BRD4 / APP / PTGS2 family

BRD4 family - Sensory Perception

bengamide aclioquinolcloxyquinnitroxolineoxyquinoline
Shown
5 / 5
Med. studies
0
IDF-Jaccard
≥ 0.15
Top pathways
Sensory PerceptionPlatelet degranulationToll Like Receptor 4 (TLR4) Cascade

Computational hypothesis · not a clinical claim

Research SignalLevel C
9
score

TNF / ACHE family

TNF family - Potassium Channels

amsacrineganoderic acid bganoderiol fhoechst 33258ungeremine
Shown
5 / 5
Med. studies
0
IDF-Jaccard
≥ 0.15
Top pathways
Potassium ChannelsVoltage gated Potassium channelsMuscle contraction

Computational hypothesis · not a clinical claim

Research SignalLevel C
8
score

TNF / BRD4 / IL1B family

TNF family - Innate Immune System

iberdomidelenalidomidepomalidomide
Shown
3 / 3
Med. studies
0
IDF-Jaccard
≥ 0.15
Top pathways
Innate Immune SystemInterleukin-1 family signalingInterleukin-1 processing

Computational hypothesis · not a clinical claim

ExploratoryLevel C
6
score

SLC2A4 family

SLC2A4 family - Integration of energy metabolism

bay 876cytochalasin bglucose
Shown
3 / 3
Med. studies
0
IDF-Jaccard
≥ 0.15
Top pathways
Integration of energy metabolismCellular hexose transportVitamin C (ascorbate) metabolism

Computational hypothesis · not a clinical claim

ExploratoryLevel A
5
score

SIRT3 / SIRT1 / ABL1 family

SIRT3 family - Downstream signaling events of B Cell Receptor (BCR)

adenosine diphosphateadenosine triphosphateergosterolsuramin
Shown
4 / 4
Med. studies
300
IDF-Jaccard
≥ 0.15
Top pathways
Downstream signaling events of B Cell Receptor (BCR)Activation of NF-kappaB in B cellsAdaptive Immune System

Computational hypothesis · not a clinical claim

TYPE 2 — TARGET CLUSTER0 results

Target-Convergence Clusters

Multiple understudied compounds converging on the same high-value molecular target. Each cluster is a potential multi-compound hypothesis.

No target clusters found.

All discoveries are hypothesis candidates based on computational analysis of PubMed data and molecular target graphs — not confirmed mechanisms. X-Vault seals provide cryptographic proof of discovery timestamp and corpus version. Clusters and families are previews only; sealing available on request. Patent: EVE-PAT-2026-001 · Organiq Sweden AB